Trial Profile
Progression-free Survival After Minimally Invasive Surgical Microwave Ablation Plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer: MIMIPAC Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms MIMIPAC
- 11 Feb 2024 This trial has been completed (End Date: 29 Jan 2024), according to European Clinical Trials Database record.
- 24 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2020 Status changed from not yet recruiting to recruiting.